Febuxostat (FBS) has emerged as a revolutionary treatment
for hyperuricemia and gout. This comprehensive review provides a pioneering
analysis of the instrumental role of Liquid Chromatography with Mass
Spectrometry (LC-MS) in unravelling the bioavailability and bioequivalence of
Febuxostat (FBS) in human plasma. Utilizing Febuxostat d9 and d7, along with
other drugs as internal standards (IS), the review steers through the intricate
view of pharmaceutical research, focusing on validation methods and the challenges
presented by the complex pharmacokinetics of FBS. Unprecedented in its depth,
the review aims to contribute valuable insights to the field by addressing the
evolving paradigms in pharmaceutical analysis. FBS, a revolutionary advancement
in the treatment of hyperuricemia and gout, takes centre stage, highlighting
its pivotal role in contemporary therapeutic approaches. LC-MS develops as a
cornerstone analytical method for studying FBS, offering unparalleled
sensitivity and selectivity. The review delves into the sample preparation
techniques, emphasizing the significance of protein precipitation and
liquid-liquid extraction in extracting FBS from human blood plasma. LC-MS/MS,
chosen for its exceptional sensitivity and specificity, becomes a focal point
in FBS analysis, with IS employed to enhance accuracy. The optimization of
chromatographic conditions, encompassing the careful selection of stationary
and mobile phases, is highlighted as crucial for establishing a robust and
reliable LC method, ensuring accuracy in pharmacokinetic studies of FBS. This
review positions LC-MS as a cornerstone analytical technique, highlighting its
critical role in the precise determination of Febuxostat in blood plasma, with
significant implications for future bioavailability and bioequivalence studies.
The study concluded that LC-MS's superiority in Febuxostat analysis set the
stage for a future where pharmacokinetic studies become insightful, efficient,
and transformative, shaping the future of pharmaceutical research.
Author(s)details:-
Atchaya Chakravarthy
(Master of Pharmacy)
Department of Pharmaceutics, JSS College of Pharmacy, Ooty, Tamil Nadu–643
001, India.
Sanjuktha Vimal
(Majoring in Human Biology and Neuroscience)
Department of Biology, University of Toronto, Ontario–M5S3H2, Canada.
Please See the book
here :- https://doi.org/10.9734/bpi/prrat/v9/3108
No comments:
Post a Comment